Moderna, Inc. Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent
Moderna, Inc. (MRNA) reported Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent · last filed 2026-07-31
- Moderna, Inc. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Moderna, Inc. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2026-03-31 was $0.00.
- Moderna, Inc. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2025-09-30 was -$2.00M.
- Moderna, Inc. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2025-06-30 was $1.00M.
| Period end | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 3 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 6 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 9 month |
|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-07-31 | $0.00 10-Q · filed 2026-07-31 | |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-01 | ||
| 2025-09-30 | -$2.00M 10-Q · filed 2025-11-06 | -$1.00M derived: sum of 2 quarters · filed 2026-07-31 | -$3.00M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $1.00M 10-Q · filed 2026-07-31 | -$1.00M 10-Q · filed 2026-07-31 | |
| 2025-03-31 | -$2.00M 10-Q · filed 2026-05-01 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-01 | $0.00 10-Q · filed 2025-08-01 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |